Axxam is focused on the development of small molecule drugs with the ability to target inflammation directly.
Axxam is focused on the development of small molecule drugs with the ability to target inflammation directly. The company was founded in 2011 and is based in Milan, Lombardia.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Dec 14, 2016
Acousia Therapeutics
|
Series A | €2.50M | Biotechnology | — |